Skip to main content
. 2020 Oct 19;23(11):101697. doi: 10.1016/j.isci.2020.101697

Figure 3.

Figure 3

Drug Set Enrichment Analysis and Enriched Drug-Target Associations

(A and B) (A) Dot plot visualization of enriched drug-target associations in all SARS2 including the generated consensus cosine score. Drug set enrichment analyses were performed against 295 drug-target families. Only those with absolute enriched score ES ≤ −0.5 and an FDR <0.25 are shown. (B) ACE2_GTEX settings. Drug set enrichment analyses were performed against 295 drug-target families. Only those with absolute enriched score ES ≥ 0.5 and an FDR <0 .25 are shown.

(C and D) (C) GSEA plot of the cosine signature for Janus kinase 2 inhibitors in SARS2_A549_ACE2_RUXO drug set enrichment analysis and (D) GSEA plot of the cosine signature for Bruton kinase inhibitors in ACE2_GTEX drug set enrichment analysis.

(E) Heat plot showing all enriched drug-target families with putative dual activities: restoring both ACE2 co-expression partners in the lungs and pathway perturbations following SARS-CoV-2 infection.